Carnegie Institution of Washington

University of Pennsylvania

Johns Hopkins University

Steven A Farber

Michael Pack

Marnie Halpern

James H Thierer

We describe a high-throughput, phenotypic screening method for one or more modulator(s) of Apolipoprotein B (ApoB) in larval zebrafish. The modulator(s) may be enhancers or inhibitors of ApoB expression. This represents a remarkable opportunity to investigate drug targets in every cell and tissue type of a whole animal without bias, thus maximizing the likelihood of identifying viable pre-therapeutic leads for compounds or biologics in a subject (e.g., human).

High-throughput, in vivo screening platform for modulators of Apolipoprotein B

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid and/or cholesterol processing in a vertebrate; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism in the vertebrate.

High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds

The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid processing; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism.

Growing community of inventors

Baltimore, MD, United States of America

Steven A Farber